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Abstract This review will summarize the impact of vitamin
D deficiency on muscle health. Mechanistic evidence regard-
ing the presence of the specific vitamin D receptor in muscle
tissue and muscle biopsy abnormalities observed with
deficiency will be reviewed, as well as molecular and non-
molecular effects of vitamin D in muscle tissue. At the clinical
level, the evidence from randomized controlled trials of
vitamin D supplementation on functional improvement and
fall reduction will be summarized. Further, the manuscript will
discuss whether vitamin D effects on fall prevention modulate
in part its benefit on fracture prevention and why fall
prevention is essential in fracture prevention at higher age.
Finally, trial and epidemiological data will be reviewed to
assess desirable serum 25-hydroxyvitamin D levels for optimal
muscle health.
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1 Introduction
Four lines of evidence support a role of vitamin D in
muscle health. First, proximal muscle weakness is a
prominent feature of the clinical syndrome of vitamin D
deficiency [1]. Clinical findings in vitamin D deficiency
myopathy include proximal muscle weakness, diffuse
muscle pain, and gait impairments such as waddling way
of walking [2]. Second, the vitamin D receptor (VDR) is
expressed in human muscle tissue [3, 4], and VDR
activation may promote de novo protein synthesis in muscle
[5, 6]. Mice lacking the VDR show a skeletal muscle
phenotype with smaller and variable muscle fibers and
persistence of immature muscle gene expression during
adult life [7, 8]. These abnormalities persist after correction
of systemic calcium metabolism by a rescue diet [8]. Third,
several observational studies suggest a positive association
between 25-hydroxyvitamin D (25(OH)D) and muscle
strength or lower extremity function in older persons [9,
10]. Fourth, vitamin D supplementation increases muscle
strength and balance [11, 12], and reduces the risk of falling
in community-dwelling individuals [12–14], as well as in
institutionalized individuals [11, 15] in several double-blind
randomized-controlled trials (RCTs) summarized in a 2009
meta-analysis discussed below [16].
1.1 VDR in skeletal muscle tissue
The presence of the VDR in skeletal muscle tissue has been
questioned recently by Wang and DeLuca suggesting that the
VDR is undetectable in muscle tissue [17]. Wang and
DeLuca’s findings are in contrast with many earlier studies
[3, 18–21], including the most recent one by Ceglia and
collagues using a new multi-step immunofluorescent tech-
nique to detect the VDR in muscle biopsy tissue from older
female subjects [4]. Ceglia and collagues used 3 commercially
available anti-bodies to the VDR, including the D-6 Santa Cruz
monoclonal antibody used byWang and DeLuca, and detected
the VDR in muscle with each of the three anti-bodies [4].
The presence of a nuclear VDR in muscle tissue suggests
that the effect of vitamin D on muscle is most likely direct via
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a genomic transcriptional effect. Mechanistically, it has been
suggested that 1,25-dihydroxyvitamin D binds to the nuclear
VDR in muscle resulting in de novo protein synthesis [5, 6].
At a clinical level, this is supported by findings of two small
trials in older adults (see paragraph below), which docu-
mented an increase in type II muscle fibers after treatment
with 1-alpha-calcidiol [22] or vitamin D2 [23].
In addition to the relatively slow genomic effect of
vitamin D on muscle mediated by its nuclear receptor, a
non-genomic rapid effect of vitamin D on muscle tissue has
been suggested. The non-genomic effect has been found to
support calcium transport into the muscle cell relevant to
muscle contraction [24, 25]. This effect may be mediated
by a VDR located in the cell-membrane of muscle fibers as
recently suggested by findings from Ceglia and colleagues.
Their data support the presence of a VDR inmuscle cell nuclei
and suggest a peripheral VDR staining pattern unrelated to the
nuclei [4].
One study quantified VDR expression in human skeletal
muscle tissue biopsies from 32 orthopedic surgery patients by
immunohistological staining of the VDR using a monoclonal
rat antibody to the VDR (Clone no. 9A7) [3]. In the
multivariate analysis, older age was a significant predictor
of decreased VDR expression (number of VDR positive
nuclei) after controlling for biopsy location (gluteus medius
or the transversospinalis muscle), and 25-hydroxyvitamin D
status. An age-related decline in VDR expression is
supported by studies in rats where VDR expression declined
with advancing age in both intestine [26, 27] and bone [26].
Whether vitamin D supplementation increases VDR expres-
sion in muscle is not known to date.
1.2 Vitamin D receptor knockout mouse model
Mice lacking the VDR have key abnormalities that may
serve as a model of what severe vitamin D deficiency may
cause in humans [28]. Further, the ability to maintain
calcium homeostasis in these mice by a recue diet allows
insight in actions of the VDR that are critical for normal
development independent of its role in calcium homeostasis
[29, 30]. Based on these studies an important function of
the VDR has been identified in several target tissues,
including muscle [28]. Compared to their wild type litter
mates, mice lacking the VDR have variable muscle fibers
that are 20% smaller in diameter at 3 weeks of age (prior to
weaning), and this difference is even more pronounced at
8 weeks of age [8]. Notably, these abnormalities in VDR
knock-out mice persist after correction of systemic calcium
metabolism by a rescue diet [8] and therefore support a role
of the VDR in muscle development and maturation that is
based on a direct effect of vitamin D on muscle unrelated to
calcium metabolism.
1.3 Vitamin D deficiency and type II muscle atrophy
in humans
Muscle biopsy studies in humans suggest a potentially
selective effect of vitamin D on type II muscle fibers. First,
patients with osteomalacic myopathy reveal type II muscle
atrophy in muscle histology investigations [31]. Second, in
two smaller clinical trials treatment with 1-alpha-calcidiol
[22] or vitamin D2 [23] increased type II muscle fibers in
older adults. Sorenson and colleagues performed one small
uncontrolled study with muscle biopsies taken at baseline
and after 3 month of treatment with 0.5 micrograms of
1-alpha-calcidiol per day in 11 postmenopausal women with
osteoporosis [5]. The authors documented a relative change
in fiber composition with an increase in the diameter and
number of type II muscle fibers after a 3 month of treatment
[5]. In the second randomized controlled study among 48
senior stroke survivors by Sato and colleagues, similar
findings were observed after 2-years of treatment with
1000 IU ergocalciferol per day [23].
Type II muscle atrophy in profound vitamin D deficiency,
and the observed increase of type II fast-twitch muscle fibers
with vitamin D treatment from the two small trials fit well with
the findings that high dose vitamin D supplementation (700 to
1000 IU per day) reduced the risk of falling by 34% in a meta-
analysis of 8 double-blind randomized controlled trials [32]
(see section on fall prevention below). Type II muscle fibers
are fast-twitch fibers and therefore are the first to be recruited
when fast reaction is needed, such as in the prevention of a
fall. Notably, ageing itself has been associated with a
decrease in type II fast-twitch relative to type I slow-twitch
muscle fibers [33]. Given the high prevalence of vitamin D
deficiency in senior adults, it is possible that the age related
decline in type II muscle fibers is in part explained by vitamin
D deficiency, which may be accompanied by a decrease in
muscular VDR expression with age [3].
1.4 Is there 1-alpha hydroxylase activity in muscle?
The 1α-hydroxylase enzyme (CYP27B1) performs the con-
version of 25(OH)D into 1,25(OH)2D. Its classic location is
the kidney, however more recently the enzyme has been
observed in many human cells and tissues [34] including
vascular smooth muscle cells [35]. Whether 1α-hydroxylase
activity is present also in skeletal muscle is undefined to date.
Children with 1α-hydroxylase deficiency due to mutations
in the enzyme (vitamin D dependent rickets type 1/pseudovi-
tamin D deficiency rickets) present with a clinical picture of
joint pain and deformity, hypotonia, growth failure and
muscle weakness [36]. Notably, muscle weakness in these
children is rapidly reversible with physiologic doses of
calcitriol or 1α-hydroxyvitamin D [37]. In support of a
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concept that the 1α-hydroxylase activity is present in muscle
tissue, myopathy in patients with “regular” vitamin D
deficiency rickets or osteomalacia is reversible with cholecal-
ciferol or ergocalciferol supplementation [2, 38].
1.5 Vitamin D and function and strength
Most observational studies show a positive association
between higher 25(OH)D status and better lower extremity
function in older adults. Higher 25(OH)D levels were
associated with a lower risk of functional decline [39, 40], a
lower risk of future falls and a lower risk of nursing care
admission [41], including two population-based studies from
the US [10] and Europe [39].
Consistently, in several trials of older individuals at risk for
vitamin D deficiency, vitamin D supplementation improved
strength, function, and balance [11, 12, 14]. Most impor-
tantly, these benefits translated in a reduction in falls in some
of the same trials [11, 12, 14]. In three recent double-blind
RCTs supplementation with 800 IU vitamin D3 resulted in a
4–11% gain in lower extremity strength or function [11, 12],
and an up to 28% improvement in body sway [12, 14] in
older adults age 65+ within 2 to 12 month of treatment.
Extending to trials among individuals with a lower risk of
vitamin D deficiency and including open design trials, a recent
meta-analysis by Stockton identified 17 RCTs that tested any
form of vitamin D treatment and documented a muscle strength
related endpoint. The authors suggested that based on their
pooled findings, vitamin D may not improve grip strength, but
a benefit of vitamin D treatment on lower extremity strength
could not be excluded (p=0.07) among individuals with 25
(OH)D starting levels of >25 nmol/l and the authors report a
significant benefit among two studies with participants that
started with 25(OH)D levels <25 nmol/l [42].
1.6 Vitamin D benefits on fracture prevention
may be in part explained by muscle benefit
The beneficial effect of vitamin D on calcium absorption
and bone mineral density may not be the only explanation
for its protective effect against fractures [43]. In fact,
vitamin D deficiency may cause muscular impairment even
before adverse effects on bone occur [44]. Further,
supported by the presence of the VDR in human muscle
tissue [3] and an early (within 2 to 5 months) [11, 15] and
sustained [13, 45–47] effect of vitamin D on falls [16], the
observed fracture reduction with vitamin D may be
modulated in part by its benefit on muscle. Moreover, the
early effect of vitamin D supplementation on fall prevention
[16] may explain a fracture reduction that was apparent
within 6 months of treatment in the Boston STOP-IT [48]
and the Decalyos I studies [49].
A dual-benefit vitamin D on bone and muscle is especially
attractive among seniors who have a high incidence of non-
skeletal risk factors for fracture [50]. Mechanistically, fractures
at later age are closely linked to muscle weakness [51] and
falling [52, 53]. Over 90% of fractures occur after a fall and
fall rates increase with age [54] and poor muscle strength or
function [54]. While the circumstances [50] and the direction
[55] of a fall determine the type of fracture, bone density and
factors that attenuate a fall, such as better strength or better
padding, critically determine whether a fracture will take
place when the faller lands on a certain bone [56].
Additionally, fear of falling may adversely affect bone density
through self-restriction of physical activity [57, 58]. After
their first fall, about 30% of persons develop fear of falling
[57], resulting in decreased mobility and quality of life [57].
Notably, anti-resorptive therapy alone is not adequate treat-
ment in elders with muscle weakness and other risk factors
for falls [59].
1.7 Anti-fall efficacy of vitamin D
Several recent peer-reviewed meta-analyses of randomized,
controlled trials have addressed the effect of vitamin D on
fall risk reduction [16, 60–67], all of them suggesting a
benefit. Thus, given the available evidence today, vitamin
D supplementation for fall prevention should not be
delayed as a recommendation among the senior population.
This suggestion is in line with the Agency for Healthcare
Research and Quality (AHRQ) for the U.S. Preventive
Services Task Force [66], the 2010 American Geriatric
Society/British Geriatric Society Clinical Practice Guideline
[68], the 2010 assessment by the IOF [69], and the 2011
recommendations on vitamin D by the Endocrine Society
[70], all 4 of which identified vitamin D as an effective
intervention to prevent falling in older adults.
Challenging for their assessment is that falls tend to be
forgotten if not associated with significant injury [71],
requiring short periods of follow-up and well defined
ascertainment strategies. Thus, one recent meta-analysis
assessed the efficacy of vitamin D supplementation based
on double-blind RCTs that also used a high quality fall
assessment [16, 32]. Notably, restricting the evidence to
double-blind RCTs with a high-quality fall assessment, fall
prevention was observed only in trials with a treatment dose
of 700 to 1000 IU vitamin D per day [32]. Any lower
dose of vitamin D supplementation did not reduce fall risk
(see Fig. 1).
The recent 2010 Institute of Medicine (IOM) Report
claimed that the peer-reviewed meta-analysis illustrated in
Fig. 1 may have been flawed regarding the choice of 8 trials
and the method chosen to explain heterogeneity. In a
rebuttal [32], the authors confirmed their selection of trials
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and re-analyzed their data to account for the stochastic
dependencies (correlations) between the corresponding risk
ratios in the multiple dosing trial by Broe et al. as suggested by
the IOM. In the re-analysis, when treatment was the only
predictor (regardless of dose level), there was a significant
reduction in the odds of falling based on the primary analysis
of the same 8 trials: OR=0.73 [.62, .87]; p=.0004. When the
model was expanded to capture the impact of both high dose
and low dose treatment (see Fig. 1), high dose vitamin D
(700 to 1000 IU vitamin D per day) reduced the odds of
falling by 34% (OR=0.66 [.53, .82] p=.0002), while low
dose vitamin D did not (OR=1.14 [.69, 1.87]; p=.61) [32].
Notably, in the original publication of this meta-analysis
[16], the authors performed a sensitivity analysis including
15 trials of any study design and fall assessment quality (n=
17,786) and documented a non-significant 7% fall reduction
with vitamin D (RR=0.93; 95% CI 0.87–1.01). Even at the
comprehensive analysis level, significant variation among
the 15 trials (Q-test: p=0.009), could be explained by dose
(700 IU +/day; n=17,281; pooled RR was 0.92 (95% CI,
0.85–1.00)), and further among trials that tested a higher
dose by trial quality (Q-test: p=0.005). Further, based on the
primary analysis [16], the benefit of fall prevention was
present in all subgroups of the senior population at the higher
dose of vitamin D. At the higher dose of 700 to 1000 IU
vitamin D, there was a 38% reduction in the risk of falling
with a treatment duration of 2 to 5 months and a sustained
significant effect of 17% fall reduction with treatment duration
of 12 to 36 months, and the benefit was independent of type of
dwelling and age. There was a suggestion that vitamin D3 was
superior to vitamin D2 for fall prevention. Although the
number of studies for active vitamin D and fall prevention
was small, the authors pooled these trials separately and
found a significant benefit on fall prevention (−22%), which
adds to the evidence that improved vitamin D status will
reduce the risk of falling in older individuals.
1.8 Summary of the IOM report recommendations
of vitamin D and fall prevention
The IOM did a thorough review on the effect of vitamin D on
fall prevention. Their synopsis is that the evidence of vitamin
D on fall prevention is inconsistent, which is in contrast to all
published and peer-reviewed meta-analyses [16, 60–67] and
recent guidelines by the Agency for Healthcare Research and
Quality (AHRQ) for the U.S. Preventive Services Task Force
[66], the American Geriatric Society/British Geriatric Society
Clinical Practice Guideline [68], position paper on vitamin D
by the IOF [69], and the Endocrine Society [70].
The IOM overall analysis of 12 RCTs (n=14,101)
showed a significant benefit of vitamin D on fall prevention
(OR=0.89; 95% CI 0.80–0.99), as did the majority of their
subset analyses, clearly supporting the use of vitamin D in
the prevention of falling. The set of analyses which showed
Fig. 1 Fall prevention by dose of vitaminD. Circles show the relative risk
of falling in 8 double-blind RCTs testing vitamin D supplementation with
or without calcium supplementation against calcium or placebo. Markers
filled indicate trials with oral vitamin D3 (cholecalciferol) and markers
unfilled indicate trials with oral vitamin D2 (ergocalciferol) [16, 32]. By
visual inspection, fall reduction only occurs in trials that tested a vitamin
D dose of at least 700 IU per day. Including all trials (regardless of dose
level), there was a significant reduction in the odds of falling: OR=0.73
[.62, .87]; p=.0004. When the model is expanded to capture the impact
of both high dose and low dose treatment, high dose vitamin D (700 to
1000 IU vitamin D per day) reduced the odds of falling (OR=0.66
[.53, .82] p=.0002), while low dose vitamin D did not (OR=1.14
[.69, 1.87]; p=.61)
Fig. 2 Fall prevention by achieved 25(OH)D levels. Circles show the
relative risk of falling in 5 double-blind RCTs testing vitamin D
supplementation with or without calcium supplementation against
calcium or placebo documenting achieved 25(OH)D levels in the
treatment groups. Markers filled indicate trials with oral vitamin D3
(cholecalciferol) and markers unfilled indicate trials with oral vitamin D2
(ergocalciferol) [16, 32]. By visual inspection, fall reduction only occurs
in trials that achieve 25(OH)D levels of at least 60 nmol/l in their
treatment groups. Achieved serum 25-hydroxyvitamin D concentrations
of 60 nmol/l or more resulted in 23% fall reduction (pooled RR=0.77;
95% CI; 0.65–0.90), while less than 60 nmol/l resulted in no fall
reduction (pooled RR=1.35, 95% CI, 0.98–1.84) [10]
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no benefit were based on only 4 studies, which cannot be
considered reliable indicators of true treatment efficacy, as
these trials either used low dose vitamin D [72], had less than
50% adherence [73], had a low-quality fall assessment [74]
or used one large bolus dose of vitamin D among seniors in
unstable health [75].
1.9 Desirable 25-hydroxyvitamin D status for muscle health
A threshold for serum 25(OH)D level needed for muscle
function and fall prevention in older subjects has been
evaluated in few studies. A dose–response relationship
between lower extremity function and serum 25(OH)D levels
has been found in two epidemiologic studies among older
individuals [9, 10]. From these analyses a threshold of
50 nmol/l has been suggested for optimal function in one
study [9], while in the larger study [10], a threshold beyond
which function would not further improve was not identified,
but most of the improvement was seen coming from very
low 25(OH)D levels to a minimal threshold of 60 nmol/
l [10]. Consistently, one meta-analysis of double-blind RCTs
found a differential benefit of achieved 25(OH)D levels
below 60 nmol/l versus levels 60 nmol/l or above, with a
benefit demonstrated only in the higher group. Achieved
serum 25-hydroxyvitamin D concentrations of 60 nmol/l or
more resulted in 23% fall reduction (pooled RR=0.77; 95%
CI; 0.65–0.90), while less than 60 nmol/l resulted in no fall
reduction (pooled RR=1.35, 95% CI, 0.98–1.84) [10]; see
Fig. 2.
Lending further support to the importance of an adequate
dose of vitamin D, several double-blind RCTs have docu-
mented fracture prevention with 700–800 IU vitamin D per
day [48, 49, 74, 76] but not with 400 IU per day [77–79].
2 Conclusion
Vitamin D is relevant to muscle health as supported by several
lines of evidence summarized in this article. Based on available
data, the VDR is present in muscle tissue and vitamin D effects
on muscle are direct including both genomic and non-genomic
effects. Strong evidence is available from clinical trials in the
senior population suggesting that vitamin D supplementation
at a high enough dose reduces the risk of falling. Thus, given
the available evidence today, vitamin D supplementation for
fall prevention should not be delayed as a recommendation
among the senior population. More studies are needed to test
whether higher doses of vitamin D than currently recommen-
ded (600 to 800 IU/day) contribute to a greater benefit on
muscle, including both muscle function and fall prevention.
Further, additional studies are needed to further defined
vitamin D effects at the cellular level in muscle and whether
VDR expression can be enhanced by treatment.
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